The following is a summary of “Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine,” published in the March 2025 issue of Journal of Primary Care & Community Health by Rosari et al. Basal and intermediate insulins come in U-100 (glargine, determir, NPH) or ultra-long-acting (ULA) U-200 […]
The post Switch from U-100 to U-200 or U-300 Insulin Improves Clinical Outcomes first appeared on Physician’s Weekly.
